2-(pyridin-2-yldisulfanyl)ethyl N-methylcarbamate

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 2-(pyridin-2-yldisulfanyl)ethyl N-methylcarbamate
• 化学式: C₉H₁₂N₂O₂S₂
• 分子量: 244.338
• InChiKey: AYZHHQYWIVOATE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  15
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  102
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  2-(pyridin-2-yldisulfanyl)ethyl N-methylcarbamate 在 吡啶 、 nitrosonium tetrafluoroborate 作用下， 以 乙腈 为溶剂， 反应 2.0h， 生成 2-(pyridin-2-yldisulfanyl)ethyl N-methyl-N-nitrosocarbamate
  参考文献：
  名称：

  [EN] ANTICANCER DRUGS AND METHODS OF MAKING AND USING SAME
  [FR] MÉDICAMENTS ANTICANCÉREUX ET LEURS PROCÉDÉS DE PRODUCTION ET D'UTILISATION

  摘要：

  本发明提供了用于改善抗癌药物的生物分布和/或特异性的药物修饰。在某些实施例中，本发明的化合物包括药物、连接剂和核心酸。核心酸可以变化以调节化合物在体内的性质，使得化合物更有选择性地分布到肿瘤并在细胞质中活跃或变得活跃。

  公开号：

  WO2020154672A1
• 作为产物：
  描述：

  2-(2-吡啶基二硫代)乙醇 在 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 16.0h， 生成 2-(pyridin-2-yldisulfanyl)ethyl N-methylcarbamate
  参考文献：
  名称：

  [EN] ANTICANCER DRUGS AND METHODS OF MAKING AND USING SAME
  [FR] MÉDICAMENTS ANTICANCÉREUX ET LEURS PROCÉDÉS DE PRODUCTION ET D'UTILISATION

  摘要：

  本发明提供了用于改善抗癌药物的生物分布和/或特异性的药物修饰。在某些实施例中，本发明的化合物包括药物、连接剂和核心酸。核心酸可以变化以调节化合物在体内的性质，使得化合物更有选择性地分布到肿瘤并在细胞质中活跃或变得活跃。

  公开号：

  WO2020154672A1

文献信息

• [EN] Anticancer Drugs and Methods of Making and Using Same<br/>[FR] MÉDICAMENTS ANTICANCÉREUX ET LEURS PROCÉDÉS DE FABRICATION ET D'UTILISATION
  申请人：UNIV YALE

  公开号：WO2019023621A1

  公开（公告）日：2019-01-31

  The present invention provides drug modifications for improving biodistribution and/or specificity of an anticancer drug. In certain embodiments, the compound of the invention comprises a drug, a linker and a core acid. The core acid can be varied to tune the properties of the compound within the body such that the compound more selectively distributes to tumors and is, or becomes active in the cytosol.

  本发明提供了用于改善抗癌药物的生物分布和/或特异性的药物修饰。在某些实施例中，本发明的化合物包括药物、连接剂和核酸。核酸可以变化以调节化合物在体内的性质，使得化合物更具选择性地分布到肿瘤并在细胞溶质中活跃或变得活跃。
• PROTEIN-POLYMER-DRUG CONJUGATES
  申请人：Mersana Therapeutics, Inc.

  公开号：US20170348424A1

  公开（公告）日：2017-12-07

  A drug conjugate is provided herein. The conjugate comprises a protein based recognition-molecule (PBRM) and a polymeric carrier substituted with one or more -L D -D, the protein based recognition-molecule being connected to the polymeric carrier by L P . Each occurrence of D is independently a therapeutic agent having a molecular weight ≦5 kDa. L D and L P are linkers connecting the therapeutic agent and PBRM to the polymeric carrier respectively. Also disclosed are polymeric scaffolds useful for conjugating with a PBRM to form a polymer-drug-PBRM conjugate described herein, compositions comprising the conjugates, methods of their preparation, and methods of treating various disorders with the conjugates or their compositions.
• ANTICANCER DRUGS AND METHODS OF MAKING AND USING SAME
  申请人：YALE UNIVERSITY

  公开号：US20210085796A1

  公开（公告）日：2021-03-25

  The present invention provides drug modifications for improving biodistribution and/or specificity of an anticancer drug. In certain embodiments, the compound of the invention comprises a drug, a linker and a core acid. The core acid can be varied to tune the properties of the compound within the body such that the compound more selectively distributes to tumors and is, or becomes active in the cytosol.
• [EN] HYDROXY-POLMER-DRUG-PROTEIN CONJUGATES<br/>[FR] CONJUGUÉS HYDROXY-POLYMÈRE-MÉDICAMENT-PROTÉINE
  申请人：MERSANA THERAPEUTICS INC

  公开号：WO2014093640A1

  公开（公告）日：2014-06-19

  A drug conjugate is provided herein. The conjugate comprises a protein based recognition-molecule (PBRM) and a polymeric scaffold having one or more -LD-D, the PBRM being connected to the polymeric scaffold by Lp, wherein the polymeric scaffold comprises a linear, branched or cyclic polymer having four or more -OH groups. Each occurrence of D is independently a therapeutic agent having a molecular weight < 5 kDa. LD and Lp are linkers connecting the therapeutic agent and PBRM to the polymeric scaffold respectively. Also disclosed are polymeric scaffolds useful for conjugating with a PBRM to form a polymer-drug-PBRM conjugate described herein, compositions comprising the conjugates, methods of their preparation, and methods of treating various disorders with the conjugates or their compositions.